thenewsfacts.com
  • Home
  • Latest News
  • Trending News
  • Entertainment
  • Technology
  • Sports
  • Business
  • Health
thenewsfacts.comthenewsfacts.com
Font ResizerAa
Search
  • Home
  • Latest News
  • Trending News
  • Entertainment
  • Technology
  • Sports
  • Business
  • Health
Follow US
© thenewsfacts : All Rights Reserved.

Home » India Approves COVAXIN for Children 6 to 12 Years Age

COVID Vaccines

India Approves COVAXIN for Children 6 to 12 Years Age

TheNewsFacts
Last updated: April 26, 2022 7:34 pm
TheNewsFacts
Share
India Approves COVAXIN for Children 6 to 12 Years Age
SHARE

Hyderabad: India has approved COVAXIN for children 6 to 12 years of age today. Bharat Biotech, a global leader in vaccine innovation and developer of vaccines for infectious diseases, announced that BBV152 (COVAXIN), its whole-virion inactivated COVID-19 vaccine candidate, has received emergency use approval in children 6-12 years of age.

Covaxin for children facts to know

  • COVAXIN was earlier approved for children 12-18 years of age.
  • Whole-Virion inactivated SARS-CoV-2 Vaccine (BBV152) has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study in children 2-18 years of age.
  • Neutralizing antibodies in children on were 1.7 times higher than in adults.
  • No serious adverse event was reported. Pain at the injection site was the most commonly reported adverse event. No cases of myocarditis or blood clots were reported, as is to be expected with inactivated vaccines.
  • COVAXIN exhibits robust immune responses in children with 2 doses and 6 months follow up, indicating durability of immune responses. Data was presented to the CDSCO Subject Expert Committee and will be published in the weeks to come.

Covaxin for Children Facts

Covaxin for Children
Covaxin for Children Update

Bharat Biotech had conducted phase II/III, open-label, and multicenter studies to evaluate the safety, reactogenicity, and immunogenicity COVAXIN® in healthy children and adolescents in the 2-18 age group. The clinical trials conducted in the paediatric population between June 2021 to September 2021 have shown robust safety, reactogenicity, and immunogenicity. The data readouts were submitted to the Central Drugs Standard Control Organisation (CDSCO) during October 2021, and received emergency use nod for children aged 12-18 from DCGI during December 2021.

Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, “We have established COVAXIN® as an universal vaccine for adults and children. Safety of the vaccine is critical for children and we are glad to share that COVAXIN® has now proven data for safety and immunogenicity in children. We have achieved our goal of developing a safe and efficacious COVID-19 vaccine for adults and children.”

Clinical trials in children documented seroconversion at 95-98%, four weeks after the second dose, indicating superior antibody responses in children when compared to adults and also displayed Th1 bias. In earlier COVAXIN studies in adults, cross reactive memory T cells against all variants of concern was reported. Data from neutralization studies against Delta and Omicron variants have been published along with impact of cell mediated immune responses. Since COVAXIN, is an inactivated vaccine corroborative results are expected in children similar to that of adults.

Booster dose of COVAXIN® in adults, generated robust neutralizing antibody responses against both Omicron (B.1.529) and Delta (B.1.617.2) using a live virus neutralization assay. 100% of test serum samples showed neutralization of the Delta variant and more than 90% of serum samples showed neutralization of the Omicron variant. These data add to the body of evidence that the broad-spectrum mechanism of action of a whole virus inactivated COVID-19 vaccine, like COVAXIN® (BBV152), is a viable option in this continuously evolving pandemic

COVAXIN® is formulated uniquely such that the same dosage can be administered to adults and children alike. COVAXIN® is a ready-to-use a liquid vaccine, stored at 2-8C, with 12 months shelf life and multi-dose vial policy. The same vaccine can also be used for 2 dose primary immunization and for booster dose vaccinations, making it truly an universal vaccine.
Fresh stocks of COVAXIN® are available and ready for supplies. Bharat Biotech has readily available more than 50 million doses of COVAXIN in vials, and more than 200 million doses as drug substance. Additional production capacity is also available to meet product demand.

About Bharat Biotech : More about COVAXIN® – https://www.bharatbiotech.com/covaxin.html

TAGGED: Covaxin 6 to 12 years, COVAXIN FOR CHILDREN, Covaxin for Kids, Covaxin News
Share This Article
Twitter Email Copy Link Print
Previous Article Chhavi Mittal is Now Cancer Free, Urges Fans Don't Stop Prayers Chhavi Mittal is Now Cancer Free, Urges Fans Don’t Stop Prayers
Next Article Elon Musk Twitter has 3 New Promises to Fulfill Elon Musk Twitter has 3 New Promises to Fulfill

Your Trusted Source for Accurate and Timely Updates!

We're committed to providing accurate and unbiased news as it unfolds, earning the trust of a large audience. Stay informed with our news updates on the latest events and trends, keeping you ahead of the curve.
FacebookLike
TwitterFollow
InstagramFollow

Popular Posts

Patanjali Baba Ramdev’s Apology Falls Flat: Supreme Court Demands Action

New Delhi, April 2, 2024: The Supreme Court of India has rejected Yoga Guru and…

By NewsFacts Bureau

Smriti Mandhana Historic Feat, Quickest to complete 3000 ODI runs

Indian Women Cricket newest Superstar Mandhana became the quickest India women's player and the third…

By TheNewsFacts

How The Brain Develops – Indian Scientist Develops New Study Model

Yogita K. Adlakha, an Indian Scientist and a recipient of INSPIRE Faculty fellowship instituted by…

By TheNewsFacts

You Might Also Like

Covaxin BHU Study
COVID VaccinesLatest News

Covaxin BHU Study: BB Points Flaws in Data Points, Backs Strong Safety Track Record

By NewsFacts Bureau
COVAXIN
COVID Vaccines

COVAXIN production to be demand-driven, says Bharat Biotech

By TheNewsFacts
iNCOVACC: Bharat Biotech Reveals World's 1st Nasal COVID Vaccine Price
COVID Vaccines

iNCOVACC: Bharat Biotech Reveals World’s 1st Nasal COVID Vaccine Price

By TheNewsFacts
Bharat Biotech iNCOVACC Vaccine priced ₹800 in CoWIN, ₹325 for the Govt Supplies, Rollout in January 2023
COVID Vaccines

Bharat Biotech iNCOVACC Vaccine priced ₹800 in CoWIN, ₹325 for the Govt Supplies, Rollout in January 2023

By TheNewsFacts
thenewsfacts thenewsfacts

About US


TheNewsFacts: Brings you the interesting facts, news facts and updates from India an the world across politics, tech, entertainment, business, tending, and more. We deliver what you love to read.
Top Categories
  • Latest News
  • Trending News
  • Paris Olympics 2024
  • Sports
  • Entertainment
  • Business
  • Technology
Usefull Links
  • About The News Facts
  • Latest News
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Contact Us
Follow us
Facebook Twitter Instagram

© thenewsfacts. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?